TRAFFIC ADVISORY:

President Trump is scheduled to be in Philadelphia on Tuesday, September 15, 2020 at The National Constitution Center (NCC) in the Independence Mall area. Increased police presence is anticipated in Center City throughout Tuesday afternoon and evening. Please allow extra time if you are going to Wills Eye. Please be advised of area street closures to vehicles beginning at 1:00PM on Tuesday 9/15. Pedestrian access will also be limited in the area. This is subject to change and area restrictions, which could widen, will be lifted once the President departs the NCC. There are also demonstrations planned for Tuesday 9/15 around Independence Mall as well as City Avenue.

Retina Clinical Trials – Macular Degeneration

MACULAR DEGENERATION CLINICAL TRIALS

Neovascular (Wet) Age-Related Macular Degeneration

Longer-Acting Pharmacologic Agents
These new medical compounds are being studied to determine their efficacy and safety in comparison to the current standard anti-VEGF agents. Administered by intravitreal injection, they may potentially achieve a longer therapeutic effect.

Kodiak Sciences (DAZZLE)*
A study to evaluate the efficacy and safety of KSI-301, an anti-VEGF antibody biopolymer conjugate, versus Aflibercept in patients with neovascular (wet) age-related macular degeneration. (DAZZLE). Learn more.

Graybug Vision (ALTISSIMO)
A depot formulation of Sunitinib Malate (GB-102) compared to Aflibercept in subjects with neovascular (wet) age-related macular degeneration (ALTISSIMO). Learn more.

Roche/Genentech (TENAYA)
A study to evaluate the efficacy and safety of Faricimab in participants with neovascular age-related macular degeneration (TENAYA). Learn more.

Roche/Genentech (LUCERNE)
A study to evaluate the efficacy and safety of Faricimab in participants with neovascular (wet) age-related macular degeneration (LUCERNE). Learn more.

Novartis (MERLIN)
Study of safety and efficacy of Brolucizumab 6 mg dosed rvery 4 weeks compared to Aflibercept 2 mg dosed every 4 weeks in patients with retinal fluid despite frequent anti-VEGF injections (MERLIN). Learn more.

Chengdu Kanghong (PANDA)
Efficacy and safety trial of Conbercept intravitreal injection for neovascular (wet) age-related macular degeneration (PANDA-1). Learn more.

Aerie
A study assessing AR-13503 implant alone and in combination with Aflibercept in subjects with nAMD or DME. Learn more.

Port Delivery System (PDS)
PDS is a small surgical implant that is intended to slowly release ranibizumab, a well-established anti-VEGF medication. The aim is to reduce the need for intravitreal injections and the implant can be refilled with a special syringe in the office setting.

Roche /Genentech (ARCHWAY)
A Phase III study to evaluate the port delivery system with Ranibizumab compared with monthly Ranibizumab injections in participants with neovascular (wet) age-related macular degeneration (Archway). Learn more.

Roche /Genentech (PORTAL)
Extension study for the port delivery system with Ranibizumab (Portal). Learn more.

Gene Therapy
These technologies utilize different non-disease-causing viral vectors to carry and deliver a coding sequence for a soluble anti-VEGF protein. In essence the goal is for anti-VEGF medication to be manufactured by cells in the eye, which will hopefully reduce the need for frequent intravitreal injections.

Regenexbio
RGX-314 gene therapy for neovascular (wet) age-related macular degeneration trial. This viral vector is administered as a single dose via subretinal delivery during outpatient surgery. Learn more.

Adverum Biotechnologies (OPTIC)
ADVM-022 intravitreal gene therapy for neovascular (wet) age-related macular degeneration (OPTIC). This viral vector is administered by a one-time intravitreal injection. Learn more.

Dry Age-Related Macular Degeneration

Anti-Inflammation
Inflammation is implicated in the pathophysiology of atrophy and vision cell loss in advanced dry AMD. Pharmacologic agents designed to block or modulate various parts of the inflammation process may slow the progression and development of geographic atrophy.

OAKS
Study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration. Learn more.

Genentech (GALLEGO)
A study assessing the safety, tolerability, and efficacy of RO7171009 in participants with geographic atrophy secondary to dry age-related macular degeneration (GALLEGO). Learn more.

Ophthotech
Zimura (anti-C5 aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration. Learn more.

Boehringer Ingelheim Pharmaceuticals
Safety, tolerability, and pharmacokinetics of single doses BI 425809. Learn more.

University of Virginia TOGA
Clinical study to evaluate treatment with ORACEA® (oral doxycycline) for geographic atrophy (TOGA). Learn more.

Cell Based
Cell based therapy involves the subretinal surgical delivery of stem cells to replace or regenerate dysfunctional cells and tissue caused by dry AMD.

Astellas (AIRM)
A Phase 1b dose escalation evaluation of safety and tolerability and a Phase 2 proof of concept investigation of efficacy and safety of ASP7317 for atrophy secondary to dry age-related macular degeneration. Learn more.

Lineage/Cellcure*
Safety and efficacy study of OpRegen for treatment of advanced dry age-related macular degeneration. Learn more.

Genetic Screening
As our collective understanding about the complex genetics behind the development of advanced dry AMD continues to increase, therapeutic agents will likely begin to target specific sub-types or genetic variants of dry AMD. 

MedSpace (Gyroscope Therapeutics)
To evaluate the natural progression of dry age-related macular degeneration. Learn more.

Gemini Therapeutics
A genetic screening and registry study to evaluate long-term clinical outcomes and disease progression in subjects with non-central geographic atrophy (GA) who are carriers of high-risk genetic complement variants associated with dry age-related macular degeneration (AMD).

*pending